{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 458275734
| image = 
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = o
| target = B-lymphoma cell
<!-- Clinical data -->
| tradename = 
| pregnancy_AU = 
| pregnancy_US = 
| pregnancy_category = 
| legal_AU = 
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = 
<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 
<!-- Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 145832-33-3
| ATC_prefix = none
| ATC_suffix = 
| PubChem = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
<!-- Chemical data -->
| chemical_formula = 
| molecular_weight = 
}}

'''Detumomab''' is a [[mouse]] [[monoclonal antibody]]<ref>[http://whqlibdoc.who.int/inn/proposed_lists/prop_INN_list70.pdf WHO Drug Information]</ref> developed for the treatment of cancer.{{Citation needed|date=September 2009}}

==References==
{{reflist}}

{{Monoclonals for tumors}}

[[Category:Monoclonal antibodies for tumors]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}